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Abstract
Quercetin has been reported to act as a senolytic by selectively removing senescent endo-
thelial cells, and thus it would seem quercetin could revolutionize the field of gerontology.
However, given quercetin’s narrow therapeutic index reported in work done with human
umbilical vein endothelial cells (HUVECs), we hypothesized that quercetin is not innocuous
for non-senescent adult human vascular endothelial cells at concentrations that have been
reported to be safe for proliferating HUVECs. Furthermore, we investigated quercetin 3-D-
galactoside (Q3G; hyperoside), an inactive quercetin derivative that needs to be cleaved by
beta-galactosidase overexpressed in senescent cells to release quercetin, as a potential
safer senolytic. We compared the effectiveness of quercetin and Q3G in primary human cor-
onary artery endothelial cells (HCAEC), which are adult microvascular cells. We found that
quercetin caused cell death in non-senescent endothelial cells at a concentration that has
been reported to selectively remove senescent cells, and that Q3G was not cytotoxic to
either young or senescent cells. Thus, in primary adult human endothelial cells, quercetin
and Q3G are not senolytics. Earlier work reporting positive results was done with HUVECs,
and given their origin and the disparate findings from the current study, these may not be the
best cells for evaluating potential senolytics in clinically relevant endothelial cells.
New and noteworthy
Previously, quercetin has been reported to be a senolytic, a drug that selectively removes
senescent cells, in HUVECs. However, we found neither quercetin nor Q3G was effective
as a senolytic for adult human endothelial cells.
Introduction
Quercetin is a flavonoid found in significant quantities in our diet with beneficial effects,
including anti-thrombotic, anti-inflammatory, and anti-neoplastic properties [1–4]. It is an
excellent antioxidant that scavenges many naturally occurring reactive oxygen species,
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including O2
- and ONOO−, and it facilitates zinc trafficking into cells, which in turn functions
as an antioxidant [5, 6]. However, quercetin has been reported to induce cell type-specific
cytotoxicity in vitro, where quercetin was relatively harmless to murine thymocytes and
human lung embryonic fibroblasts at 100 μM, but significantly increased cell death was
observed in human umbilical vein endothelial cells (HUVECs) at the same concentration [7,
8]. Despite this, following the finding that clinically relevant concentrations of glutathione
completely suppressed quercetin’s mutagenicity, and that no significant harm was observed in
animals fed quercetin, it was determined to be safe for human consumption [9].
Quercetin 3-D-galactoside (Q3G), also known as hyperoside, is a natural derivative of quer-
cetin produced by Hypericumperforatum L. (St. John’s Wort) [10]. Q3G is structurally identical
to quercetin, except for a galactoside group attached through an O-glycosidic bond that can be
cleaved by beta-galactosidase to liberate quercetin [11]. Like quercetin, Q3G is bioactive with
its anti-oxidant properties, even when it is not pre-processed by beta-galactosidase, and has
other beneficial functions including inhibiting the growth of several parasites, lowering choles-
terol, and fostering cardioprotection after ischemia [10, 12]. In addition, although quercetin-
induced cytotoxicity has been reported in non-senescent HUVECs, Q3G is much safer for
these cells, yet still confers protective anti-oxidative effect [13]. The major focus of quercetin
research has been on its anti-oxidative effects. However, a groundbreaking new role for quer-
cetin has been recently proposed, which may also extend to the quercetin derivative Q3G,
based on recently reported findings that quercetin has senolytic properties, or the ability to
selectively remove senescent cells. This would be an important development given the contri-
bution of senescent cells to many of the deleterious changes of aging, including increased
inflammation [14].
The in vivo development of cellular senescence, where cells halt normal function, irrevers-
ibly cease dividing, and secrete damaging inflammatory factors, has been proposed to be one
of the major drivers of aging [15]. Cellular senescence is characterized by several prominent
biochemical and functional changes, including flattened and enlarged cell morphology,
increased lysosomal beta-galactosidase activity, and inflammatory factor secretion [15, 16].
The idea of cellular senescence contributing to the aging process is supported by the finding
that senescent cells accumulate in aging organisms and at sites of age-related dysfunction, such
as atrophic skin, osteoarthritic lesions, and atherosclerotic plaques [17].
Recent work reporting quercetin’s potential as a senolytic used irradiation-induced senes-
cent HUVECs, but HUVECs, which are derived from the umbilical vein of newborns, are far
removed from aging adult human arterial vascular endothelial cells (EC). Not surprisingly,
important differences have been found between adult EC and HUVEC [18–21]. Furthermore,
quercetin’s low therapeutic/toxic ratio in the HUVEC study [14] raised the possibility that
quercetin could significantly injure non-senescent cells. It was unclear whether the prolifera-
tion of non-senescent cells could be compensating for some of the quercetin-mediated cell
death, thus masking its toxicity to the young cells at the lower concentrations found to be
selectively cytotoxic to senescent cells. In the current study, we used adult human coronary
artery endothelial cells (HCAEC), which are microvascular cells, as a relevant model, and gen-
erated two groups of cells from them to better understand the effect of quercetin: EP (early pas-
sage; young) and SEN (senescent), as a model of an aging tissue.
Given the known differences between adult EC and HUVECs, we hypothesized that querce-
tin would exhibit nonspecific cytotoxicity to adult EC. We investigated the effect of quercetin
on EP vs. SEN HCAEC, and whether the SEN group was more susceptible to quercetin toxicity,
as had been seen in irradiation-induced senescent HUVECs [14]. Furthermore, we tested
whether Q3G, an inactive pro-drug that generates quercetin when cleaved by beta-galactosidase
Quercetin and hyperoside as senolytics
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overexpressed in senescent cells, would more selectively remove senescent cells, and thus be a
safer senolytic.
Materials and methods
Cell culture
HCAEC from three different adult human female donors, frozen at passage 3, were purchased
[Cell Applications (San Diego, CA, USA) Lot#2228, Cell Applications Lot#2827, Lonza
(Mapleton, IL, USA) Lot# 396592]. Donor information for the cells, supplied by the vendors,
is as follows: #2228 (21 years old, Caucasian female), #2827 (17 years old, Hispanic female),
#396592 (32 years old, Caucasian female). The cause of death and medical history for the
donors is personal protected information, and thus unavailable. Common causes of death in
younger females are accidents (30–40% of deaths), suicide and homicide (9–18%) [22]. Endo-
thelial cell identity has been confirmed by uptake of acetylated LDL and presence of Factor III.
Mycoplasma testing was negative. The cells were cultured in VascuLIFE1 VEGF-MV (Lifeline
Cell Technology; Frederick, MD, USA), containing 5% FBS, 5 ng/mL FGF, 50 μg/mL ascorbic
acid, 10 mM L-Glutamine, 15 ng/mL IGF-1, 5 ng/mL EGF, 5 ng/mL VEGF, and 0.75 U/mL
heparin sulfate. Antibiotics and hydrocortisone were not used. Cells were seeded at 3000 cells/
cm2 for each passage. Culture medium was changed every two days, and the cells were kept in
a 5% CO2 humidified incubator at 37˚C.
Establishment of EP and SEN cells
The HCAEC were thawed and allowed to proliferate (Passage 1). After 4 days, they were pas-
saged (Passage 2), and were then cryogenically stored with 2X freezing buffer [40% FBS (GE
Life Sciences; Marlborough, MA, USA), 40% VascuLIFE1 VEGF-MV (Lifeline Cell Technol-
ogy), 20% DMSO (Sigma-Aldrich; St. Louis, MO, USA), 100 IU Penicillin-Streptomycin
(Thermo Fisher Scientific; Waltham, MA, USA)]. At the time of an experiment, a vial was
thawed and cultured for 4 days to allow time for recovery. The subsequent passage (Passage 3)
was considered EP, where treatment of quercetin or Q3G began 2 days after this point for 48
hours.
To establish SEN cells, the cells were serially passaged every 4 days and re-plated at the den-
sity of 3000 cells/cm2, thereby gradually decreasing the cells’ proliferation from the initial rate
of 10- to 30-fold increase between passages to less than 2-fold increase. When the proliferation
rate had decreased to the point where the cell number failed to double within 4 days, the subse-
quent passage was considered SEN. Once the passage at which the cells undergo senescence
was identified, a different batch of cells was harvested 3- to 4- passages before reaching this
point and was cryogenically stored until desired for experiments. We opted to freeze the cells
at 3- to 4- passages before reaching senescence, rather than 1 passage prior like the EP cells,
because we were concerned the senescent cells may be more prone to injury by the freezing
process at this late passage due to their characteristic enlarged cell size. Cellular senescence was
confirmed through visual inspection for the characteristic flattened and enlarged morphology,
senescence-associated beta-galactosidase (SABG) staining, and decreased expression of Lamin
B1 [23]. Thus, cellular senescence and SEN group were operationally, visually, and biochemi-
cally defined and established in our study.
Quercetin and Q3G preparation and treatment
Quercetin (CAS# 117-39-5; Cat# 10005169) and Q3G (CAS# 482-36-0; Cat# 18648) were pur-
chased from Cayman Chemical (Ann Arbor, MI, USA). The stock solutions for these
Quercetin and hyperoside as senolytics
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chemicals were prepared in DMSO at the concentration of 20 mM, aliquoted into small air-
tight tubes, and were stored in either liquid nitrogen or -80˚C. Quercetin has been reported to
degrade once it is in solution [24]. To prevent this, each of the stock aliquots kept in -80˚C was
used within a month of preparation and discarded after the single thaw for the experiment, as
storing at low, freezing temperatures was recommended by other investigators and one sup-
plier (Abcam) [25–27].
For treatment of HCAEC, quercetin and Q3G were first diluted in the culture medium to
create working stock solutions, and then these solutions were mixed in different proportions
with the culture medium to achieve the concentrations needed for the experiments. The blank
culture medium had the same concentration of DMSO as the working stock solutions, so all
cells were treated with the same concentration of DMSO. These working solutions were pre-
pared immediately prior to treatment, and were applied to subconfluent cells two days after
cell seeding. Based on the preliminary data on cell viability with quercetin/Q3G treatment
(data not shown), both EP and SEN cells were treated for 48 hours at the end of their last pas-
sages (Fig 1A) at 0.21 mL per cm2 of growth area.
Western blot
Whole-cell lysates were prepared by scraping the cultured cells in radio-immunoprecipitation
assay (RIPA) buffer containing protease and phosphatase inhibitors (Sigma Aldrich; St. Louis,
MO, USA; Cat# P8340, Cat# P0044). The samples were sonicated to facilitate cell lysis, and
then centrifuged at 500g for 5 minutes to remove unlysed cells. The samples were separated on
a 10% SDS-PAGE gel under reducing and denaturing conditions, and then transferred to
nitrocellulose membranes for western blot, as previously described[28]. The following
Fig 1. A) The experimental timeline. Cells were treated with either quercetin or Q3G for 48 hours before assays. B) A representative SABG
staining comparing EP and SEN cells. Many of the SEN cells show characteristic flattened morphology, and are stained blue due to increased
SABG activity. C) Representative image of the western blot and densitometry data for Lamin B1. *p<0.05 vs. baseline (N = 3 samples/group, per
donor), T-test.
https://doi.org/10.1371/journal.pone.0190374.g001
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antibodies were used for probing: Lamin B1 (Cell Signaling; Danvers, MA, USA; Cat# 15068),
and beta-actin (Sigma Aldrich; St. Louis, MO, USA; Cat# A2228)
Senescence-associated beta-galactosidase staining
SABG staining was carried out according to a previously published protocol [29]. Briefly, EP
and SEN cells were fixed with a formaldehyde-glutaraldehyde buffer, and incubated with the
X-gal staining solution overnight at 37˚C. The cells were then washed with DPBS (Dulbecco’s
phosphate-buffered saline) and kept in the buffer during light microscopy imaging to prevent
desiccation and deformation of cells.
As an alternate assay to confirm the findings for this study, the SABG stained cells were
manually counted. To minimize bias, counting of the cells was done by researchers blinded to
the cell treatment group. For counts, a well in the culture plate was positioned on the micro-
scope stage without looking into the eyepiece, preventing subconsciously choosing a particular
field of view to assay. Then, without re-positioning the plate, both stained and non-stained
cells visible in the field of view were counted.
Cell proliferation assay
The DNA content-based fluorescence assay, CyQUANT1 Cell Proliferation Assay Kit (Cat#
C7026), was purchased from Thermo Fisher Scientific. HCAEC were grown and treated with
quercetin/Q3G in black 96-well tissue culture microplates with a clear bottom. Then, t0
(immediately before treatment) and Day 2 (48 hour treatment) plates were washed with DPBS
(containing Ca++ and Mg++, to prevent cell detaching) and stored at -80˚C. Both plates were
treated with the supplied DNA-sensitive fluorescence dye and analyzed at the same time with a
microplate reader (Molecular Devices; Sunnyvale, CA, USA), following the manufacturer’s
protocol.
Live-Dead assay
Cell viability was measured with the LIVE/DEAD1 Fixable Green Dead Cell Stain Kit for 488
nm Excitation (Cat# L23101, Thermo Fisher Scientific). EC were grown on six-well tissue cul-
ture plates, and the cells were washed twice with DPBS containing Ca++ and Mg++ immedi-
ately prior to quercetin/Q3G treatment to remove the small amount of floating dead cells and
debris that routinely occur with cell culture. After 48 hours of treatment, the following from
each well were collected and centrifuged at 500 rcf for 5 minutes to obtain mixtures of live and
dead cells: conditioned culture medium, cells detached with trypsin-EDTA, and DPBS-well
washes. Then, the assay was performed according to the manufacturer’s protocol for flow
cytometry, with formaldehyde fixation. Non-fragmented whole cells were identified and gated
with the forward scatter (FSC) parameter (S1A and S1B Fig).
Statistics
Multiple groups were compared using a one-way ANOVA, and Kruskal-Wallis and Mann-
Whitney U tests were used for the whole quercetin or Q3G data if data in any group were not
normally distributed (Figs 2 and 3). Normally distributed data consisting of only two groups
per donor was compared by T-test (Figs 1C and 4). SigmaPlot (Systat Software; San Jose, CA,
USA) and SPSS v.23 (IBM; North Castle, NY, USA) were used for all statistical analyses. Data
is reported as the mean ± the standard error of the mean (SEM). A p< 0.05 was considered
significant.
Quercetin and hyperoside as senolytics
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Results
For all experiments, HCAEC isolated from three different female donors were used to account
for individual genetic variations, and only the data points that were positive for all three
donors were considered relevant. For example, if only two of the three donors showed toxicity
at a certain concentration of quercetin or Q3G, then this concentration was not considered
damaging.
Establishment of EP and SEN cells
Similar numbers of passages (10 to 13) were required to reach senescence with characteristic
morphologic changes and expression of SABG (Fig 1B), as well as decreased expression of
Lamin B1 (Fig 1C), for the three donors. For each donor, the passage number for onset of
Fig 2. Relative cell abundance following quercetin A) and Q3G B) treatment of EP and SEN from three different donors. Cell proliferation
was measured 48 hours after treatment, and was compared against the baseline count of cells frozen just prior to beginning treatment
(t0). Values significantly lower than the t0 are indicated by asterisks. *p<0.05 vs. baseline (N = 16 wells/group, per donor), Kruskal-Wallis
and Mann-Whitney U tests.
https://doi.org/10.1371/journal.pone.0190374.g002
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senescence was highly reproducible. The experimental time line is summarized in Fig 1A. A
small subset of cells was still proliferating at this stage, as indicated by the cell proliferation
assay, discussed below (Fig 2), but the overwhelming majority of the cells showed the charac-
teristic morphological changes associated with cellular senescence, including the enlargement
and flattening of the cells.
Anti-proliferative effect of quercetin, but not Q3G, in EP and SEN cells
The proliferation of ECs was assessed following treatment with either quercetin or Q3G (Fig
2). The cell counts for both EP and SEN cells were increased in the respective 0 μM (vehicle
only) groups compared to baseline values at Day 0 ("t0"), reflecting their natural proliferation
over 48 hours (Fig 2A). Cell counts decreased with the increasing concentration of quercetin,
Fig 3. Live-Dead assay for quercetin (A) and Q3G (B) treatment of EP and SEN cells from the same three different donors. Data reflect the
percentage of dead cells in response to different concentrations of quercetin or Q3G. N 6 wells/group, per donor. Approximately 1000
non-fragmented cells were scored for each N. *p<0.05 vs. baseline value. One-way ANOVA was used for Q3G data, which are normally
distributed. Kruskal-Wallis and Mann-Whitney U tests were used for quercetin treatment to account for non-normality.
https://doi.org/10.1371/journal.pone.0190374.g003
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consistent with a dose-dependent anti-proliferative effect, which has been previously reported
in various cell types [2]. However, when the cell counts dropped below the initial baseline
value, this suggested that cell death had occurred. At 6 μM quercetin, SEN cell numbers for all
three donors were significantly lower than their respective baseline values (p 0.004). EP cells
did not manifest quercetin toxicity until 10 μM, consistent with SEN cells’ increased sensitivity
to quercetin’s cytotoxicity. In contrast, Q3G did not reduce the cell proliferation even at
100 μM, except for SEN cells from one donor, where a small, but significant dip in cell counts
occurred (Fig 2B).
Quercetin toxicity to EP and SEN EC
The Live-Dead assay was performed with flow cytometry to directly assess cell death with
quercetin/Q3G treatment (S1A and S1B Fig; Fig 3). This assay revealed quercetin-mediated
toxicity in EP cells at a lower concentration than our previously determined threshold of
10 μM (Fig 2A): EP cells from all three donors had a significant increase in cell death when
treated with 6 or more μM of quercetin (Fig 3A). Thus, the EP cells’ apparent resistance to
quercetin-induced cell death exhibited in the cell proliferation assay (Fig 2) was likely due the
lost cells being replaced by proliferation, thereby masking quercetin’s toxicity. As for SEN
cells, results similar to EP cells were observed (Fig 3), where all three donors also had signifi-
cantly elevated cell death beginning at 6 μM, suggesting non-specific toxicity of quercetin.
Q3G did not affect cell death at any concentration in EP or SEN cells (Fig 3B). Thus, the Live-
Dead assay clearly demonstrates an increase in cell death in EP cells, as well as SEN cells, rather
than selective culling of SEN cells.
Quercetin and Q3G treatment on the prevalence of senescent cells
To directly assess whether senescent cells treated with quercetin or Q3G decreased in number,
we used direct counting of SABG stain-positive cells by researchers blinded to treatment
groups (Fig 4). SEN cells were treated with 6 μM quercetin based on the cell proliferation data,
Fig 4. Manual quantification of SABG stain-positive cells. SEN cells from the same three donors were treated with 6 μM quercetin and
100 μM Q3G followed by SABG staining. Manual counting was done to assess percent of SABG positive cells. *p<0.05 vs. baseline value
(N = 12 wells/group, per donor, where each N ranged from 40 to 160 cells). T-test was used to determine statistical significance between
control and test groups for each donor.
https://doi.org/10.1371/journal.pone.0190374.g004
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which had indicated that this concentration was nontoxic for EP cells, but reduced the number
of SEN cells (Fig 2). For Q3G, 100 μM was used to determine if it was capable of reducing the
number of senescent cells. The SEN cells treated with 6 μM quercetin showed no reduction in
SABG stain-positive, senescent cells (Fig 4). Paradoxically, we found an increase in the popula-
tion of senescent cells for two of the three donors treated with 100 μM Q3G, but as not all
donors showed the same response, we deemed this inconclusive. Thus, neither quercetin nor
Q3G reduced the prevalence of senescent cells.
Discussion
Previously, quercetin was reported to be a senolytic in irradiation-induced senescent HUVECs
[14]. HUVECs are derived from the umbilical cord of newborn babies, and for a long time
were the only model of primary human EC; however, these cells are not the best model of dis-
eases associated with human arterial aging. HUVECs have been shown to differ substantially
from primary endothelial cells derived from adult human vasculature [18–21]. In the current
study, we investigated whether quercetin is a senolytic in adult EC, and evaluated whether
Q3G would be a more selective senolytic. Our key findings are that quercetin at a concentra-
tion that reduced SEN EC also caused significant EP EC cell death (Fig 3), and that there was
no evidence of senescent cell-specific cell death mediated by quercetin (Fig 4). Thus, quercetin
is not a selective senolytic in adult human arterial endothelial cells, where both EP and SEN
cells responded similarly to quercetin’s toxicity. In contrast, Q3G had no significant cytotoxic-
ity at all (Figs 2B, 3B and 4).
In this study, we performed three different assays to evaluate quercetin and Q3G. Our SEN
cells are a mixture of senescent cells positive for SABG staining (25 to 45%) and near-senescent
cells, which are beginning to show the characteristic morphological changes related to cellular
senescence, but are SABG stain-negative and slowly proliferate (Figs 1, 2 and 4). As cellular
senescence induced by replication, which is a physiologically relevant stress, and ionizing radi-
ation, have similar, but nevertheless distinct phenotypes [30], we think this is a more represen-
tative model of aging tissue.
SEN cells were more sensitive to quercetin treatment than EP ECs. EP cells did not begin to
show cytotoxicity until 10 μM quercetin, which differed substantially from the previous work
with HUVECs, where proliferating cells tolerated up to 20 μM quercetin [14]. HCAECs’
increased sensitivity to quercetin’s cytotoxicity compared to HUVECs is consistent with previ-
ous studies that reported HUVECs’ disparate responses compared to adult EC [18, 20].
To determine if quercetin’s toxicity in EP cells was masked by their proliferation, we directly
examined the number of dead cells. Quercetin has been reported to be capable of inducing both
necrosis and apoptosis. [31] The Live-Dead assay, which captures both types of cell death, showed
that EP cell death was increased (Fig 3) at a concentration that appeared to be safe based on the
cell proliferation data (Fig 2). Importantly, both EP and SEN cells exhibited signs of increased cell
death at the same quercetin concentration. Thus, quercetin toxicity was not selective.
In the Live-Dead assay, we evaluated only non-fragmented whole cells by flow cytometry
and thus may have undercounted cell death. Therefore, we manually counted senescent cells
treated with quercetin or Q3G (Fig 4) to determine if a selective decrease of senescent cells
occurred in the SEN cell mixed population. This manual count showed that neither quercetin
nor Q3G selectively decreased senescent cells.
Quercetin and the heat shock response
An important detrimental property of quercetin is inhibition of the heat shock response (HSR)
[32]. The HSR is an important cytoprotective cellular response conferred by the induction of
Quercetin and hyperoside as senolytics
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heat shock proteins (HSPs). The primary role of HSR is to mitigate proteotoxic damage stem-
ming from a wide range of stresses, including heat, radiation, inflammation, ischemia/reperfu-
sion injury, stretch, and reactive oxygen species [33–36]. However, the HSR is blunted with
aging, as lower activity of HSF1, the primary transcription factor for the HSR and HSP expres-
sion, and HSF1-mediated HSR has been observed in senescent cells [37, 38], in the aging heart
[28] and in aging humans [39, 40]. Given quercetin’s direct effect on HSF1, which downregu-
lates both its level and activation [32], treating older individuals, who would already have an
impaired HSR, with quercetin either through high dose dietary supplements or intravenous
administration as an anti-senescence treatment may have a significant downside, including
accumulation of misfolded proteins [41].
Senolytics and aging
The first study demonstrating the physiological benefits of selective removal of senescent cells
utilized transgenic progeroid mice with a novel, inducible transgene, which would eliminate
p16Ink4a-positive, senescent cells [42]. This selective removal of senescent cells was able to pre-
vent key age-related dysfunctions in the mice, including lordokyphosis, muscle atrophy, and
cataract development [42].
The first clinically relevant senolytics for humans were discussed in a study published in
2015: quercetin and dasatinib [14]. Since then, several additional senolytic agents have been
reported [43–45], and the development of this class of drugs is ongoing. Recently, geldanamy-
cin and tanespimycin, the inhibitors of heat shock protein 90 (HSP90), were identified as seno-
lytics [45]. Inhibiting HSP90 leads to the activation of HSF1 and upregulation of HSPs [46–
48], which is the opposite effect of quercetin. However, it is unclear if activation of HSF1 is
necessary for the senolytic activity of geldanamycin and tanespimycin.
Q3G as a selective alternative to quercetin
To circumvent quercetin’s toxicity on healthy, non-senescent cells, we investigated Q3G, a
derivative of quercetin with limited toxicity to endothelial cells, which is processed by SABG
enriched in senescent cells to release quercetin in situ [10–13]. Q3G could act as a selective
prodrug in senescent cells. However, Q3G had no significant toxicity to either EP or SEN EC.
The ability of Q3G to cross the cell membrane despite its large polar structure has been dem-
onstrated by its in vitro bioactivity in treated cells [49], and Q3G has been found to be able to
release quercetin through the activity of exogenous beta-galactosidase [11]. The lack of Q3G’s
toxicity in the current study may be due to Q3G being unable to enter the beta-galactosidase-
rich lysosomes [16], or alternatively, Q3G being able to translocate to the lysosomes to release
quercetin, which is further processed into an inert compound.
In conclusion, our results demonstrate that neither quercetin nor Q3G is effective as a seno-
lytic for adult EC in vitro. The difference in the findings between our work and the results of
Zhu et al. [14] may reflect the important differences between HUVECs and mature adult EC,
as well as different models of senescence–radiation vs. replicative senescence, which is a more
physiological model of aging. Given the disparity in the sources and phenotypes of the cells,
HCAECs may be a more relevant model for studying senolytics than HUVECs.
Supporting information
S1 Fig. Representative plots for flow cytometry. –A) Representative scatter plots for flow
cytometry with different concentrations of quercetin treatment. B) Representative scatter plots
for flow cytometry with different concentrations of Q3G treatment. For both panels, the num-
ber at the lower left in the plot indicates the percentage of events within the gate compared to
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the entire events shown in the plot.
(TIF)
S1 File. Raw data.
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